Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Go back to Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management| (NASDAQ: VANI) | Delayed: 1.19 -0.02 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.21 | 52 Week High | $ | |||
| Open | $1.22 | 52 Week Low | $ | |||
| Day High | $1.23 | P/E | N/A | |||
| Day Low | $1.17 | EPS | $ | |||
| Volume | 95,295 | |||||
